Serial No. 10/606,422 Reply and Amendment dated June 20, 2006 Responding to Office Action dated April 20, 2006 Docket No. ORT-1222 USA DIV

Remarks

Claims 27-46 are in the case. Claims 1-26 were previously cancelled. Claims 27-37 and 39-46 stand rejected.

Please cancel Claims 27, 32, 37 and 42 without prejudice to the later filing by Applicants of applications directed to the cancelled subject matter. Kindly amend Claims 28-31, 33-36, 38-40 and 43-45 as indicated herein above.

Claim Rejections and Objections

The claim rejections and objections in the *Office Action* are rendered most by the cancellation of Claims 27, 32, 37 and 42 and amendment of Claims 28-31, 33-36, 38-40 and 43-45.

In particular, the claims are now limited to compounds that were disclosed in the specification in Table 1, page 9 (e.g. Claim 33) and Table 2, page 12 (e.g., Claim 28). The term "therapeutically effective" has been deleted from Claims 30, 31, 35 and 36 as required by the Examiner. Claims 29, 34, 39 and 44 have been amended by deletion of the word "essentially" as required by the Examiner. The indexing of substituents relative to the header in Claim 43 has been corrected so that it is now clear that "X" in the last compound is defined as "SO₂".

Serial No. 10/606,422 Reply and Amendment dated June 20, 2006 Responding to Office Action dated April 20, 2006 Docket No. ORT-1222 USA DIV

Applicants believe that this reply is a full and complete response to the pending Office Action, and that Claims 28-31, 33-36, 38-41 and 43-46 are now in condition for allowance. Applicants respectfully request the issuance of a timely Notice of Allowance in this case.

Respectfully Submitte

Yuriy P. Stercho, Ph.D. Atterney for Applicants Reg. No. 33,797

Johnson & Johnson Office of General Counsel One Johnson & Johnson Plaza New Brunswick, NJ 08933

June 20, 2006 Tel.: (610) 240-8006 Fax: (610) 651-6940